Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Crossref DOI link: https://doi.org/10.1007/s12325-022-02220-3
Published Online: 2022-06-30
Published Print: 2022-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gu, Congling
Huang, Hui
Han, Yi http://orcid.org/0000-0003-4830-0785
Funding for this research was provided by:
Takeda Pharmaceutical Company
Text and Data Mining valid from 2022-06-30
Version of Record valid from 2022-06-30
Article History
Received: 28 April 2022
Accepted: 8 June 2022
First Online: 30 June 2022